Peter T. Loudon

TL;DR: This work supports the feasibility and safety of hESC-RPE patch transplantation as a regenerative strategy for AMD and presents the preclinical surgical, cell safety and tumorigenicity studies leading to trial approval.

TL;DR: This work discusses current therapies and emerging drug discovery efforts aimed at delivering an optimized clinical treatment strategy for gout, with a focus on studies which suggest association of hyperuricemia with common comorbidities including cardiovascular disease, renal insufficiency, metabolic syndrome and diabetes.

TL;DR: The immunogenicity and protective efficacy of PMED DNA vaccines in nonhuman primates and swine and studies that have directly compared the effectiveness of PM ED in these large animal models to existing licensed vaccines and intramuscular or intradermal delivery of DNA vaccines with a needle are reviewed.

TL;DR: It was concluded that PMED vaccination with 4microg Trivalent influenza DNA vaccine was safe and elicited immunological responses that protected human subjects from influenza; this is the first report of protection ofhuman subjects from disease by DNA vaccination.

TL;DR: This study establishes a rationale for eliminating HIV-1-infected cells by targeting cellular immune responses against stable human endogenous retroviral (HERV) antigens and identifies a second T cell response that exhibited cross-reactivity between homologous HIV- 1-Pol and HERV-K(HML-2)-Pol determinants, raising the possibility that homology between HIV-2 and HERVs plays a role in shaping, and perhaps enhancing, the T cellresponse to HIV